Fluorinated Antimalarial Compounds for Drug-Resistant Malaria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Malaria parasites, particularly Plasmodium falciparum, have developed resistance to most antimalarial drugs, necessitating the development of novel compounds as anti-malarial agents.
Innovation Solution
The development of compounds of Formulae I-VI, which are administered to a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of Formulae I-VI, optionally in combination with other therapeutic compounds or compositions, to prevent, ameliorate, or treat a malarial infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimalarial drugs are used, then malaria treatment is effective against susceptible strains, but resistance has developed in Plasmodium falciparum making most drugs ineffective
Solution Approach 1:
The patent modifies the chemical structure of lumefantrine by changing parameters such as substituting hydrogen atoms with fluorine atoms at specific positions (R4a, R4b, R4c, R4d, R4e), adding methyl groups at R2a and R2b positions, and introducing various functional groups at R1 position. These structural parameter changes create novel compounds with improved pharmacological properties and potential resistance-breaking activity against Plasmodium falciparum.
Solution Approach 2:
The patent creates composite molecular structures by combining the lumefantrine core scaffold with various functional groups and substituents (carboxylic acid groups, hydroxyl groups, fluorine atoms, methyl groups, cyclic structures). This composite approach generates molecules with enhanced biological activity and improved efficacy against resistant malaria strains.
2Reliability
If artemisinin-based combination therapy (ACT) is used, then malaria treatment effectiveness is maintained, but cost becomes prohibitive for broad use in low-income countries
Solution Approach 1:
The patent develops novel lumefantrine derivatives that could potentially serve as cost-effective alternatives to expensive ACT regimens. By creating new molecular entities with improved pharmacological profiles, the invention aims to provide affordable treatment options that maintain effectiveness while reducing cost barriers for use in low-income malaria-endemic regions.
3Reliability
If ACT is used as frontline therapy, then malaria treatment is effective, but loss of efficacy occurs against resistant strains
Solution Approach 1:
The patent systematically modifies the lumefantrine molecular structure by changing substituent parameters at multiple positions (R1-R4e), including adding fluorine atoms, hydroxyl groups, carboxylic acid groups, and cyclic structures. These parameter changes are designed to improve the compound's pharmacological properties, enhance binding affinity to parasite targets, and extend the duration of effective action against resistant Plasmodium falciparum strains.
Data Source
AI summary
Disclosed herein are compounds and compositions comprising the compounds of Formula I (I) wherein all variables are as defined herein. Further disclosed are methods for using the above compounds and compositions comprising the above compounds for the prevention, amelioration, or treatment of malarial infections alone or in combination with other therapeutic agents, including additional anti-malarial drugs.